Work

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Year: 2024

Type: article

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(24)00005-x

Authors: Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natalie Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa McKiver, Mark Cook, Paula Rodríguez-Otero

Institutions: Universitair Ziekenhuis Leuven, The University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb (United States), Hôpital Saint-Louis, University of Bologna, Emory University, Winship Cancer Institute, Centre Hospitalier Universitaire de Lille, University of Wisconsin System, University of Wisconsin–Madison, University of Wisconsin Health, Memorial Sloan Kettering Cancer Center, Universitätsklinikum Würzburg, Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Bristol-Myers Squibb (Switzerland), Clinica Universidad de Navarra

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, Celgene

OpenAlex ID: W4392215371

FWCI: 10.72

Cites: 30

Cited by: 36

Related to: 10